Clearmind Medicine announces participation in Psychedelic Medicine – Israel 2024

Clearmind Medicine concluded its participation at the Psychedelic Medicine – Israel 2024 conference. The event took place in Tel Aviv, Israel, bringing together leading experts and researchers from around the world in the field of psychedelic medicine. Clearmind’s CEO, Adi Zuloff-Shani, Ph.D., presented a talk titled “5-Methoxy-2-Aminoindane as a Binge Behavior Regulator.” Dr. Zuloff-Shani provided insights into MEAI’s potential to regulate binge behaviors, highlighting its innovative application in treating addiction-related disorders. Additionally, researchers Prof. Joseph Tam and Dr. Saja Baraghithy from the Obesity and Metabolism Laboratory at The Hebrew University of Jerusalem presented their abstract titled “5-methoxy-2-aminoindane, a mild psychedelic agent, attenuates diet-induced obesity.” Their presentation delved into the promising results of MEAI in attenuating obesity and its related metabolic complications, showcasing its potential as a therapeutic agent in obesity management. 5-Methoxy-2-Aminoindane as a Binge Behavior Regulator” Dr. Zuloff-Shani discussed the unique properties of MEAI, a psychoactive aminoindane derivative. MEAI has shown promise in reducing the desire to consume alcoholic beverages while inducing a euphoric, alcohol-like slightly tipsy, but controlled experience. This presentation explored MEAI’s potential as a regulator of binge behaviors, potentially providing a novel approach to addiction treatment. 5-methoxy-2-Aminoindane, a Mild Psychedelic Agent, Attenuates Diet-induced Obesity: Dr. Baraghithy presented her research findings on the weight loss effects of MEAI. The study demonstrated that MEAI significantly reduces overweight and adiposity in a diet-induced obesity mouse model. The researchers shared compelling evidence that MEAI reduces fat mass, preserves lean mass, improves glucose metabolism, reduces hepatic steatosis and increases energy expenditure, making it a promising therapeutic candidate for obesity management.